Tema ETF Trust | ||||||||
Tema Oncology ETF | ||||||||
Schedule of Investments | ||||||||
November 30, 2023 (Unaudited) | ||||||||
Investments | Number of Shares | Value | ||||||
COMMON STOCKS - 96.1% | ||||||||
Biotechnology - 58.6% | ||||||||
Agios Pharmaceuticals, Inc.* | 9,438 | $ | 209,807 | |||||
Arcellx, Inc.* | 3,708 | 194,781 | ||||||
Arcus Biosciences, Inc.* | 11,141 | 167,783 | ||||||
Argenx SE - ADR*^ | 1,206 | 543,436 | ||||||
BeiGene Ltd. - ADR*^ | 2,442 | 456,507 | ||||||
Blueprint Medicines Corp.* | 565 | 39,347 | ||||||
Celldex Therapeutics, Inc.* | 11,560 | 349,228 | ||||||
Cogent Biosciences, Inc.* | 12,936 | 99,219 | ||||||
CRISPR Therapeutics AG - ADR*^ | 7,266 | 484,860 | ||||||
Cullinan Oncology, Inc.* | 15,906 | 130,270 | ||||||
CureVac N.V. - ADR*^ | 14,787 | 79,850 | ||||||
Day One Biopharmaceuticals, Inc.* | 12,540 | 145,213 | ||||||
Deciphera Pharmaceuticals, Inc.* | 18,085 | 228,052 | ||||||
Exact Sciences Corp.* | 4,356 | 278,784 | ||||||
Exelixis, Inc.* | 17,959 | 391,686 | ||||||
Fusion Pharmaceuticals, Inc. - ADR*^ | 54,978 | 304,578 | ||||||
Genmab A/S - ADR*^ | 11,946 | 377,613 | ||||||
Gilead Sciences, Inc. | 6,608 | 506,173 | ||||||
Immunocore Holdings plc - ADR*^ | 3,828 | 201,850 | ||||||
ImmunoGen, Inc.* | 17,626 | 517,323 | ||||||
Incyte Corp.* | 7,524 | 408,854 | ||||||
Intellia Therapeutics, Inc.* | 16,368 | 484,984 | ||||||
Legend Biotech Corp. - ADR*^ | 4,700 | 285,854 | ||||||
Mereo Biopharma Group plc - ADR*^ | 192,329 | 401,968 | ||||||
Merus N.V. - ADR*^ | 7,194 | 177,980 | ||||||
Mirati Therapeutics, Inc.* | 2,392 | 135,746 | ||||||
Moderna, Inc.* | 3,252 | 252,680 | ||||||
MorphoSys AG*^ | 2,332 | 61,835 | ||||||
Regeneron Pharmaceuticals, Inc.* | 990 | 815,572 | ||||||
Relay Therapeutics, Inc.* | 22,110 | 174,890 | ||||||
Revolution Medicines, Inc.* | 9,250 | 215,802 | ||||||
SpringWorks Therapeutics, Inc. | 2,789 | 84,758 | ||||||
Zentalis Pharmaceuticals, Inc.* | 5,235 | 58,894 | ||||||
9,266,177 | ||||||||
Health Care Equipment & Supplies - 3.8% | ||||||||
Lantheus Holdings, Inc.* | 3,564 | 255,254 | ||||||
Siemens Healthineers AG^ (a) | 6,090 | 350,935 | ||||||
606,189 | ||||||||
Health Care Providers & Services - 4.0% | ||||||||
Guardant Health, Inc.* | 15,856 | 399,096 | ||||||
Option Care Health, Inc.* | 7,659 | 227,855 | ||||||
626,951 | ||||||||
Health Care Technology - 2.3% | ||||||||
Schrodinger, Inc.* | 11,635 | 361,732 | ||||||
Life Sciences Tools & Services - 4.7% | ||||||||
10X Genomics, Inc., Class A * | 6,270 | 272,870 | ||||||
Illumina, Inc.* | 4,623 | 471,315 | ||||||
744,185 | ||||||||
Pharmaceuticals - 22.7% | ||||||||
Arvinas, Inc.* | 6,864 | 150,802 | ||||||
AstraZeneca plc^ | 4,620 | 590,601 | ||||||
Bristol-Myers Squibb Co. | 7,463 | 368,523 | ||||||
Chugai Pharmaceutical Co., Ltd.^ | 13,926 | 490,125 | ||||||
Daiichi Sankyo Co., Ltd.^ | 21,912 | 591,178 | ||||||
Merck & Co., Inc. | 7,390 | 757,327 | ||||||
Novartis AG^ | 6,488 | 630,648 | ||||||
3,579,204 | ||||||||
TOTAL COMMON STOCKS (Cost $14,794,342) | 15,184,438 | |||||||
SHORT-TERM INVESTMENTS - 1.3% | ||||||||
Money Market Fund | ||||||||
First American Treausry Obligations Fund - Class X, 5.277% (b) | 211,740 | 211,740 | ||||||
TOTAL SHORT-TERM INVESTMENTS (Cost $211,740) | 211,740 | |||||||
TOTAL INVESTMENTS (Cost $15,006,082) - 97.4% | 15,396,178 | |||||||
OTHER ASSETS LESS LIABILITIES - 2.6% | 408,828 | |||||||
NET ASSETS - 100.0% | $ | 15,805,006 |
* Non-income producing security. | ||||
^ Foreign security. | ||||
(a) Securities purchased pursuant to Rule 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other “qualified institutional buyers.” These securities have been deemed to be liquid by the Fund’s adviser under the supervision of the Board of Trustees. As of November 30, 2023, the value of these investments was $350,935 or 2.2% of total net assets. | ||||
(b) 7-day net yield. | ||||
ADR - American Depositary Receipt | ||||
plc- Public Limited Company | ||||
The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |
Tema Oncology ETF | ||
November 30, 2023 (Unaudited) | ||
ALLOCATION BY SECTOR | ||
Sector | Percentage of Total Net Assets | |
Health Care | 96.1% | |
Money Market Fund and Other Assets and Liabilities | 3.9% | |
Total | 100.0% |
ALLOCATION BY COUNTRY | ||
Country | Percentage of Total Net Assets | |
United States | 59.3% | |
United Kingdom | 7.6% | |
Switzerland | 7.1% | |
Japan | 6.8% | |
Netherlands | 5.1% | |
Cayman Islands | 4.7% | |
Germany | 2.6% | |
Denmark | 2.4% | |
Canada | 1.9% | |
Other(1) | 2.5% | |
Total | 100.0% | |
(1) Includes cash and net other assets (liabilities). |
Tema ETF Trust | ||||||||
Tema Oncology ETF | ||||||||
Notes to Quarterly Schedule of Investments | ||||||||
November 30, 2023 (Unaudited) | ||||||||
Investment Valuation | ||||||||
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's’ own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows: | ||||||||
• Level 1 — Quoted prices in active markets for identical assets that the Fund's have the ability to access. | ||||||||
• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). | ||||||||
• Level 3 — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). | ||||||||
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. | ||||||||
The following is a summary of the inputs used to value the Fund's investments as of November 30, 2023: |
Tema Oncology ETF | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Investments | ||||||||||||||||
Common Stocks * | $ | 15,184,438 | $ | - | $ | - | $ | 15,184,438 | ||||||||
Money Market Fund | 211,740 | - | - | 211,740 | ||||||||||||
Total Investments | $ | 15,396,178 | $ | - | $ | - | $ | 15,396,178 | ||||||||
* See Schedule of Investments for segregation by industry. |